Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company centered on metabolic dysfunction-associated steatohepatitis (MASH), with its lead therapy Rezdiffra (resmetirom) and a growing pipeline of liver-directed treatments. The MDGL news feed on Stock Titan aggregates company announcements and third-party coverage so readers can follow how Madrigal’s clinical, regulatory, and commercial activities evolve over time.
News about Madrigal frequently highlights new clinical data from its Phase 3 MAESTRO program, including imaging, biomarker, and quality-of-life results in patients with MASH and compensated MASH cirrhosis (F4c). The company also issues updates on outcomes from major scientific meetings such as the American Association for the Study of Liver Diseases (AASLD) Liver Meeting and presentations at healthcare investment conferences.
Investors and healthcare observers will see regular press releases on Rezdiffra’s commercial performance, including product revenue, patient and prescriber adoption, and geographic expansion following regulatory approvals in the U.S. and Europe. Madrigal also reports on licensing transactions that expand its MASH pipeline, such as global agreements for an oral GLP-1 receptor agonist and ervogastat, a DGAT-2 inhibitor intended for combination use with Rezdiffra.
Additional news items cover corporate and capital structure developments disclosed via Form 8-K filings, including financing agreements, credit facilities, and governance matters such as annual meeting results and equity inducement awards under stock plans. For users tracking MDGL stock, this page offers a centralized view of Madrigal’s latest disclosures related to Rezdiffra, its broader MASH program, and key financial and strategic milestones. Bookmark this feed to monitor new data releases, regulatory and commercial updates, and pipeline progress that may influence the company’s long-term outlook.
Among patients with clinically significant portal hypertension (CSPH) at baseline, 65% moved to lower risk categories by year two. The study showed a statistically significant mean reduction of 6.7 kPa in liver stiffness, with 51% of patients achieving ≥25% improvement.
Notable outcomes include 35% of patients achieving liver stiffness measurements consistent with F3 fibrosis, suggesting cirrhosis reversal. The drug was well-tolerated, with common side effects including diarrhea, COVID-19, and nausea. The results support the ongoing Phase 3 MAESTRO-NASH OUTCOMES trial of Rezdiffra in compensated MASH cirrhosis.
Madrigal Pharmaceuticals announced six presentations at the upcoming EASL Congress in Amsterdam (May 7-10, 2025), featuring crucial data about their drug resmetirom for MASH treatment. The highlight is a late-breaking presentation on two-year data from patients with compensated MASH cirrhosis.
Resmetirom, the first FDA-approved medication for MASH in the US, is a daily oral liver-directed THR-β agonist. The drug showed promising results in the Phase 3 MAESTRO-NASH trial, with 91% of patients on 100mg dosage experiencing liver stiffness improvement or stabilization.
Currently under review by European regulators, Madrigal expects a CHMP opinion and EU decision by mid-2025, with potential launches starting in Germany in late 2025. The company will host an investor webcast on May 13, 2025, to review detailed two-year data from the compensated MASH cirrhosis study.
Madrigal Pharmaceuticals (NASDAQ: MDGL), a biopharmaceutical company specializing in novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has scheduled its first-quarter 2025 financial results release for Thursday, May 1, 2025, before U.S. markets open.
The company will host a live webcast at 8 a.m. Eastern Time where management will review financial and operating results. Participants are advised to register 15 minutes before the scheduled webcast, which will be accessible through the Investor Relations section of Madrigal's website. A replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced key leadership changes as company founder Rebecca Taub, M.D., transitions from Chief Medical Officer and President of R&D to Senior Scientific and Medical Advisor, while maintaining her position on the Board of Directors. David Soergel, M.D., has been appointed as the new Executive Vice President and Chief Medical Officer, effective April 21, 2025.
Dr. Taub's legacy includes pioneering the development of Rezdiffra™ (resmetirom), the first FDA-approved medicine for treating metabolic dysfunction-associated steatohepatitis (MASH). Under her leadership, Madrigal grew from a small R&D team of fewer than 10 professionals to a commercial-stage biopharma company with over 500 employees across the U.S. and Europe.
Dr. Soergel joins from Novartis, where he served as Executive Vice President and Global Head of Cardiovascular, Renal, and Metabolism Development, overseeing 10 late-stage development programs in 2024. The company currently has two fully enrolled outcomes studies of Rezdiffra underway.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has appointed Jacqualyn "Jackie" Fouse, Ph.D. to its Board of Directors, while Fred Craves, Ph.D. will retire from the Board in July 2025. Fouse brings over 30 years of healthcare industry and finance experience, having previously served as CEO of Agios Pharmaceuticals and held executive positions at Celgene , Bunge , and Alcon Laboratories.
The appointment aligns with Madrigal's strategic focus on metabolic dysfunction-associated steatohepatitis (MASH). The company aims to drive the launch of Rezdiffra, their first approved MASH treatment, expand geographically, advance their clinical program in compensated MASH cirrhosis, and build their pipeline.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported strong Q4 and full-year 2024 results for Rezdiffra™, the first FDA-approved MASH treatment. Q4 net sales reached $103.3 million, contributing to full-year sales of $180.1 million. The company ended 2024 with $931.3 million in cash and equivalents.
New two-year data from the Phase 3 MAESTRO-NAFLD-1 trial showed promising results for patients with compensated MASH cirrhosis, including a mean 6.7 kPa reduction in liver stiffness, with 51% of patients achieving ≥25% reduction. These results support Rezdiffra's potential benefit in cirrhosis patients.
Key 2024 milestones included FDA approval in March, commercial launch in April, and recognition in updated EASL and AASLD guidelines as first-line therapy. The company completed enrollment in the MAESTRO-NASH OUTCOMES trial, with data expected in 2027. European expansion is planned for H2 2025, pending EMA approval.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra™ (resmetirom). The study showed significant improvements in liver health markers:
- Patients achieved a mean 6.7 kPa reduction in liver stiffness after two years of treatment
- 51% of patients achieved ≥25% reduction in liver stiffness
- Mean liver stiffness at baseline was 25 kPa
The safety and tolerability profile remained consistent with previous trials, showing low discontinuation rates due to adverse events. While Rezdiffra is currently approved for treating adults with noncirrhotic MASH with F2 to F3 fibrosis, it is not yet approved for MASH cirrhosis patients. The company's ongoing MAESTRO-NASH OUTCOMES trial aims to establish safety and efficacy for cirrhosis treatment.
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in the upcoming 45th Annual TD Cowen Health Care Conference. The company's presentation is scheduled for Tuesday, March 4, 2025, at 11:10 A.M. ET.
The event will feature a live webcast accessible through a direct link or via Madrigal's Investor Relations Events page. For those unable to attend the live presentation, a replay option will be made available following the event.
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced it will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 26, 2025, before U.S. markets open. The company's management will host a live webcast at 8 a.m. Eastern Time to discuss financial and operating results.
Participants can access the webcast through the Investor Relations section of Madrigal's website and are advised to register 15 minutes before the scheduled start. A replay will be available approximately two hours after the live event.